Food and Drug Administration (FDA) on Wednesday approved the first vaccine against syncytial virus (RSV), the most common cause of bronchiolitis and pneumonia.
However, the Centers for Disease Control and Prevention, the U.S. federal health agency, still has to approve the injection, which will be given to adults over 60 years of age and which has been developed by the pharmaceutical giant GSK.
RSV causes lower respiratory tract involvement that is usually mild in healthy adults but, in severe cases, can lead to pneumonia and bronchiolitis, with a high mortality rate in older and younger people.
Source: (EUROPA PRESS)
